Kimberlee C. Drapkin

Kimberlee C. Drapkin

DirectoratLENZ Therapeutics· In proxies 2023–2025

Pay in FY2024+304% from the year before · LENZ Therapeutics stock +132.8% the same year

Kimberlee C. Drapkin was paid $1.1M in FY2024 (Dec), up 304%. LENZ Therapeutics stock rose 132.8% that year.

Pay$100 in the stock at the end of FY22 → $184
Pay is from the Summary Compensation Table of each LENZ Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. LENZ TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrStock in role -76%
  2. Acumen Pharmaceuticals, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Climb Bio, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Imugene LimitedPublic company
    • Director? – PresentNo stock prices for these years
  5. Kineta, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Proteostasis Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  7. TuHura BiosciencesPublic company
    • Director? – PresentNo stock prices for these years
  8. Yumanity Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • LENZ TherapeuticsDirector · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?